Til Stürmer, MD, PhD
Dr. Stürmer is an internist and epidemiologist with expertise in state of the art methods for nonexperimental treatment comparisons, including comparative effectiveness research. He has worked as a cancer epidemiologist, has over 10 year experience in analyzing claims data and merging claims data to other data sources, and is an internationally recognized leader in propensity scores and disease risk scores.
Dr. Stürmer leads UNC-Chapel Hill’s pharmacoepidemiology program, one of the oldest and largest doctoral training programs in pharmacoepidemiology; he also is director of the Center for Pharmacoepidemiology in the Department of Epidemiology.
He is a former president of the International Society for Pharmacoepidemiology and currently serves as a member on the FDA Drug Safety and Risk Management Advisory Committee.
Honors and AwardsMember Editorial Board
2013, International Society for Pharmacoepidemiology (ISPE)President Elect
2012, International Society for Pharmacoepidemiology (ISPE)Associate Editor
American Journal of Epidemiology
EPID 765 Methods and Issues in Pharmacoepidemiology | Syllabus
Since 2009, Dr. Stürmer has taught EPID 765, titled "Methods and Issues in Pharmacoepidemiology," every other year in the spring semester. This course is one of the two main courses required for students in the pharmacoepidemiology program area.
Funded through his ongoing R01 from the National Institute on Aging (R01 AG023178) since 2005, Dr. Stürmer has published over 50 methodological papers in the peer-reviewed literature highlighting advantages and limitations of propensity scores and disease risk scores when assessing the effects of medications in older adults based on nonexperimental study designs.
This work is especially important because older adults are often excluded from randomized trials and the nonexperimental assessment of treatment effects is often confounded by frailty that steers patients away from otherwise indicated treatments.
Dr. Stürmer has developed study designs and analytic methods that allow researchers to address confounding by indicating frailty, making it possible to estimate unintended and intended treatment effects in older adults in specific settings by limiting the potential for confounding. He is internationally recognized as a leader in this field.
Since 2014, Dr. Stürmer has chaired the admissions committee of the Department of Epidemiology. Previously, he represented the Department of Epidemiology in the School's APT committee.
Antidepressant class, age, and the risk of deliberate self-harm: A propensity score matched cohort study of SSRI and SNRI users in the USA. D. Azrael, Matthew Miller, V. Pate, T. Stürmer, S.A. Swanson, A. White (2014). CNS Drugs, 28(1), 79-88.
Antidepressant dose, age, and the risk of deliberate self-harm. Deborah Azrael, Matthew Miller, Virginia Pate, Til Stürmer, Sonja Swanson (2014). JAMA Internal Medicine, 174(6), 899-909.
Assessing the impact of propensity score estimation and implementation on covariate balance and confounding control within and across important subgroups in comparative effectiveness research. Kimberly Brodovicz, Cynthia Girman, Mugdha Gokhale, Tzuyung Kou, Til Stürmer, Richard Wyss (2014). Medical care, 52(3), 280-287.
Association between the choice of IV crystalloid and in-hospital mortality among critically ill adults with sepsis. Chris Beadles, Alan Brookhart, Peter Lindenauer, Brian Nathanson, Karthik Raghunathan, Soko Setoguchi, Andrew Shaw, Mihaela Stefan, Til Stürmer (2014). Critical Care Medicine.
Association between the choice of IV crystalloid and in-hospital mortality among critically Ill adults with sepsis. Chris Beadles, Alan Brookhart, Peter Lindenauer, Brian Nathanson, Karthik Raghunathan, Soko Setoguchi, Andrew Shaw, Mihaela Stefan, Til Stürmer (2014). Critical Care Medicine, 42(7), 1585-1591.
PhD, Epidemiology, University of Heidelberg, Germany, 2001
MPH, Epidemiology, Harvard University, 1993
MD, Medicine, University of Basel, Switzerland, 1984